Univ Of Mi Hospitals & Hlth Ctrs

Type: Teaching hospital
Where: Ann Arbor, MI
Medicare CCN: 230046
Received: $65,438,037 in 3,781 records, 2023 ($23,127,399 general, $42,310,638 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2023	General payment	532	$23,127,399
2023	Research payment	3,249	$42,310,638

By company

Company	Records	Amount	Years
GENZYME CORPORATION	22	$14,651,171	2023
Janssen Research & Development, LLC	103	$6,465,722	2023
AstraZeneca Pharmaceuticals LP	53	$4,360,016	2023
Merck Sharp & Dohme LLC	50	$3,457,476	2023
Amgen Inc.	17	$2,958,497	2023
Genentech, Inc.	133	$2,384,298	2023
Novartis Pharmaceuticals Corporation	18	$2,362,288	2023
Regeneron Pharmaceuticals, Inc.	660	$2,056,205	2023
E.R. Squibb & Sons, L.L.C.	36	$1,864,885	2023
Takeda Pharmaceuticals U.S.A., Inc.	95	$1,854,203	2023
PFIZER INC.	108	$1,399,752	2023
Eli Lilly and Company	13	$1,019,982	2023
ABBVIE INC.	141	$1,014,917	2023
F. Hoffmann-La Roche AG	9	$821,049	2023
Edwards Lifesciences Corporation	47	$761,146	2023
BeiGene, Ltd.	32	$745,911	2023
AstraZeneca AB	3	$739,391	2023
Blueprint Medicines Corporation	80	$719,233	2023
Eisai Inc.	37	$708,818	2023
CSL Behring	77	$664,025	2023
AstraZeneca UK Limited	9	$635,447	2023
Medtronic, Inc.	120	$619,244	2023
Aurinia Pharma U.S., Inc.	13	$616,139	2023
Celgene Corporation	14	$561,734	2023
Travere Therapeutics, Inc.	22	$495,276	2023
Boehringer Ingelheim Pharmaceuticals, Inc.	4	$484,982	2023
Otsuka Pharmaceutical Co., Ltd.	15	$470,135	2023
PTC Therapeutics, Inc.	29	$443,716	2023
Horizon Therapeutics plc	5	$425,765	2023
Genmab A/S	33	$318,401	2023
Abbott Laboratories	71	$317,243	2023
3M Company	6	$308,605	2023
Alexion Pharmaceuticals, Inc.	11	$302,673	2023
SANOFI US SERVICES INC.	30	$266,155	2023
Siemens Medical Solutions USA, Inc.	10	$259,050	2023
Astellas Pharma Global Development	4	$254,957	2023
Align Technology, Inc.	4	$254,400	2023
ModernaTX, Inc.	34	$251,343	2023
Rhythm Pharmaceuticals, Inc.	70	$246,531	2023
VERTEX PHARMACEUTICALS INCORPORATED	10	$237,250	2023
Janssen Scientific Affairs, LLC	2	$200,000	2023
Ultragenyx Pharmaceutical Inc.	32	$187,344	2023
Genmab U.S., Inc.	11	$185,846	2023
TRILLIUM THERAPEUTICS USA, LLC	22	$182,683	2023
Sumitomo Pharma America, Inc.	16	$178,334	2023
QIAGEN, LLC	8	$158,439	2023
Boston Scientific Corporation	20	$157,288	2023
SEAGEN INC.	53	$154,448	2023
National Marrow Donor Program	16	$154,285	2023
United Therapeutics Corporation	16	$141,512	2023

By nature of payment

Nature	Records	Amount
Research payment	3,249	$42,310,638
Royalty or License	96	$17,530,477
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	90	$2,780,715
Grant	59	$1,513,069
Space rental or facility fees (teaching hospital only)	166	$645,357
Consulting Fee	11	$302,576
Long term medical supply or device loan	12	$154,371
Education	70	$118,433
Charitable Contribution	9	$47,750
Debt forgiveness	17	$34,435
Food and Beverage	2	$213

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2023-12-31	Merck Sharp & Dohme LLC	$1,387,620	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Phase II trial of Pembrolizumab and Lenvatinib in Advanced,metastatic Neuroendocrine Prostate Cancer PLANE-PC	2023
2023-12-31	Merck Sharp & Dohme LLC	$181,840	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary	2023
2023-12-31	Merck Sharp & Dohme LLC	$145,540	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for	2023
2023-12-31	Merck Sharp & Dohme LLC	$119,616	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba	2023
2023-12-31	Merck Sharp & Dohme LLC	$104,877	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini	2023
2023-12-31	Merck Sharp & Dohme LLC	$76,577	Research payment	Cash or cash equivalent	WELIREG Drug, ONCOLOGY	An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc	2023
2023-12-31	Merck Sharp & Dohme LLC	$72,770	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for	2023
2023-12-31	Merck Sharp & Dohme LLC	$62,941	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advance	2023
2023-12-31	AngioDynamics, Inc.	$60,000	Long term medical supply or device loan	In-kind items and services	NanoKnife Device, Oncology Surgery		2023
2023-12-31	AngioDynamics, Inc.	$60,000	Long term medical supply or device loan	In-kind items and services	NanoKnife Device, Oncology Surgery		2023
2023-12-31	Merck Sharp & Dohme LLC	$53,616	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus P	2023
2023-12-31	Merck Sharp & Dohme LLC	$42,550	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc	2023
2023-12-31	MENARINI SILICON BIOSYSTEMS, INC.	$24,887	Research payment	In-kind items and services	Deparray Device, Diagnostics	CTC-Oncoseq	2023
2023-12-31	Merck Sharp & Dohme LLC	$21,426	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w	2023
2023-12-31	Align Technology, Inc.	$18,000	Grant	In-kind items and services	iTero Element 5D Plus Device, Orthodontics		2023
2023-12-31	Merck Sharp & Dohme LLC	$17,120	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini	2023
2023-12-31	Merck Sharp & Dohme LLC	$15,710	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advance	2023
2023-12-31	Merck Sharp & Dohme LLC	$13,831	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR	2023
2023-12-31	ABBVIE INC.	$11,031	Research payment	In-kind items and services	DURYSTA Drug, EYE CARE	Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension	2023
2023-12-31	Merck Sharp & Dohme LLC	$10,002	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad	2023
2023-12-31	KARL STORZ Endoscopy-America	$9,835	Research payment	In-kind items and services	n.a. Device, THORACOSCOPY	Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH)	2023
2023-12-31	Merck Sharp & Dohme LLC	$9,634	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad	2023
2023-12-31	Align Technology, Inc.	$9,000	Grant	In-kind items and services	iTero Element 5D Plus Device, Orthodontics		2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$8,177	Research payment	In-kind items and services		A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506	2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$7,457	Research payment	In-kind items and services	TAGRISSO Drug, Oncology	A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with	2023
2023-12-31	Merck Sharp & Dohme LLC	$7,342	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept ACE-011	2023
2023-12-31	KARL STORZ Endoscopy-America	$6,833	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	ABBVIE INC.	$6,330	Research payment	In-kind items and services		Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open	2023
2023-12-31	MENARINI SILICON BIOSYSTEMS, INC.	$6,194	Research payment	In-kind items and services	Cellsearch Device, Diagnostics	CTC-Oncoseq	2023
2023-12-31	MENARINI SILICON BIOSYSTEMS, INC.	$6,194	Research payment	In-kind items and services	Cellsearch Device, Diagnostics	CTC-Oncoseq	2023
2023-12-31	KARL STORZ Endoscopy-America	$6,083	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	MENARINI SILICON BIOSYSTEMS, INC.	$5,743	Research payment	In-kind items and services	Deparray Device, Diagnostics	CTC-Oncoseq	2023
2023-12-31	Merck Sharp & Dohme LLC	$5,732	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera	2023
2023-12-31	KARL STORZ Endoscopy-America	$5,485	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$5,383	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus	2023
2023-12-31	KARL STORZ Endoscopy-America	$4,985	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$4,853	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary	2023
2023-12-31	AngioDynamics, Inc.	$4,800	Long term medical supply or device loan	In-kind items and services	VenaCure 1470 Pro Device, ET		2023
2023-12-31	Merck Sharp & Dohme LLC	$4,768	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus	2023
2023-12-31	MENARINI SILICON BIOSYSTEMS, INC.	$4,723	Research payment	In-kind items and services	Cellsearch Device, Diagnostics	CTC-Oncoseq	2023
2023-12-31	MENARINI SILICON BIOSYSTEMS, INC.	$4,723	Research payment	In-kind items and services	Cellsearch Device, Diagnostics	CTC-Oncoseq	2023
2023-12-31	Merck Sharp & Dohme LLC	$4,656	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba	2023
2023-12-31	Merck Sharp & Dohme LLC	$4,508	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w	2023
2023-12-31	KARL STORZ Endoscopy-America	$4,329	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$4,009	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R	2023
2023-12-31	KARL STORZ Endoscopy-America	$3,574	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$3,552	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR	2023
2023-12-31	Merck Sharp & Dohme LLC	$3,483	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for	2023
2023-12-31	Merck Sharp & Dohme LLC	$3,068	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc	2023
2023-12-31	KARL STORZ Endoscopy-America	$2,843	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$2,786	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$2,746	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Stryker Corporation	$2,651	Long term medical supply or device loan	In-kind items and services	REMB Device, SURGICAL		2023
2023-12-31	Stryker Corporation	$2,651	Long term medical supply or device loan	In-kind items and services	REMB Device, SURGICAL		2023
2023-12-31	Stryker Corporation	$2,651	Long term medical supply or device loan	In-kind items and services	REMB Device, SURGICAL		2023
2023-12-31	KARL STORZ Endoscopy-America	$2,628	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Abbott Laboratories	$2,625	Research payment	In-kind items and services	ALINITY Device, Core Diagnostics	Evaluation of Traumatic Brain Injury	2023
2023-12-31	KARL STORZ Endoscopy-America	$2,464	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$2,442	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$2,442	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	ABBVIE INC.	$2,224	Research payment	In-kind items and services	SKYRIZI Biological, IMMUNOLOGY	A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (	2023
2023-12-31	KARL STORZ Endoscopy-America	$2,200	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	ABBVIE INC.	$2,142	Research payment	In-kind items and services		A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors	2023
2023-12-31	ABBVIE INC.	$2,100	Research payment	In-kind items and services		A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Mu	2023
2023-12-31	Merck Sharp & Dohme LLC	$1,871	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase II Study of Pembrolizumab MK-3475 in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymph	2023
2023-12-31	KARL STORZ Endoscopy-America	$1,832	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$1,741	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for	2023
2023-12-31	KARL STORZ Endoscopy-America	$1,510	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	AstraZeneca UK Limited	$1,477	Research payment	In-kind items and services		A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Posit	2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$1,431	Research payment	In-kind items and services		A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and	2023
2023-12-31	KARL STORZ Endoscopy-America	$1,384	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$1,296	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$1,296	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$1,164	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$1,158	Research payment	In-kind items and services		A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate	2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$1,066	Research payment	In-kind items and services	TEZSPIRE Biological, Respiratory	A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate	2023
2023-12-31	KARL STORZ Endoscopy-America	$1,039	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$1,039	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	ABBVIE INC.	$1,000	Research payment	In-kind items and services		Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco	2023
2023-12-31	KARL STORZ Endoscopy-America	$966	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$877	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$864	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus P	2023
2023-12-31	Acerta Pharma LLC	$855	Research payment	In-kind items and services	CALQUENCE Drug, Oncology	A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat	2023
2023-12-31	KARL STORZ Endoscopy-America	$838	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$838	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	ABBVIE INC.	$831	Research payment	In-kind items and services	DURYSTA Drug, EYE CARE	Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension	2023
2023-12-31	KARL STORZ Endoscopy-America	$829	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$829	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$821	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$813	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$813	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$728	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$728	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$724	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$722	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck KGaA	$689	Research payment	Cash or cash equivalent	TEPMETKO Drug, Oncology	A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemothera	2023
2023-12-31	KARL STORZ Endoscopy-America	$661	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$660	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$648	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$645	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$621	Research payment	In-kind items and services	IMFINZI Biological, Oncology	A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co	2023
2023-12-31	KARL STORZ Endoscopy-America	$592	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$534	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$534	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$525	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$521	Research payment	In-kind items and services	BREZTRI Drug, Respiratory	A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adole	2023
2023-12-31	KARL STORZ Endoscopy-America	$510	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$435	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg	2023
2023-12-31	Stryker Corporation	$425	Long term medical supply or device loan	In-kind items and services	SONOPET IQ Device, NEURO SPINE ENT		2023
2023-12-31	KARL STORZ Endoscopy-America	$414	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$410	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$341	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Medline Industries LP	$328	Debt forgiveness	Cash or cash equivalent			2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$327	Research payment	In-kind items and services	IMFINZI Biological, Oncology	This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus	2023
2023-12-31	KARL STORZ Endoscopy-America	$320	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$320	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	MENARINI SILICON BIOSYSTEMS, INC.	$320	Research payment	In-kind items and services	Deparray Device, Diagnostics	CTC-Oncoseq	2023
2023-12-31	KARL STORZ Endoscopy-America	$315	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$270	Research payment	In-kind items and services	CALQUENCE Drug, Oncology	A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat	2023
2023-12-31	KARL STORZ Endoscopy-America	$259	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$257	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Stryker Corporation	$246	Long term medical supply or device loan	In-kind items and services	STRYKER Device, SURGICAL		2023
2023-12-31	Stryker Corporation	$246	Long term medical supply or device loan	In-kind items and services	STRYKER Device, SURGICAL		2023
2023-12-31	Stryker Corporation	$246	Long term medical supply or device loan	In-kind items and services	STRYKER Device, SURGICAL		2023
2023-12-31	KARL STORZ Endoscopy-America	$214	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$213	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$197	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$132	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase II Clinical Trial of Single Agent Pembrolizumab MK-3475 in Subjects with Recurrent or Metastatic Head and Neck S	2023
2023-12-31	KARL STORZ Endoscopy-America	$124	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$120	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$116	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$99	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$84	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$74	Research payment	In-kind items and services	ENHERTU Biological, Oncology	A Phase 1b2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Phar	2023
2023-12-31	KARL STORZ Endoscopy-America	$51	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$51	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician s C	2023
2023-12-31	KARL STORZ Endoscopy-America	$50	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$50	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$37	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$25	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	KARL STORZ Endoscopy-America	$17	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$14	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized Phase 2 Study of the Combination of Pembrolizumab MK-3475 Plus Epacadostat INCB024360 with Platinum-based C	2023
2023-12-31	KARL STORZ Endoscopy-America	$9	Education	In-kind items and services	IMAGE 1 Device, VIDEOIMAGING		2023
2023-12-31	Merck Sharp & Dohme LLC	$4	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab MK-3475,SCH900475 in Combination with Et	2023
2023-12-31	AstraZeneca Pharmaceuticals LP	$3	Research payment	In-kind items and services		A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or with	2023
2023-12-29	Amgen Inc.	$700,000	Research payment	Cash or cash equivalent		Mechanisms for biospecific molecules for weight loss	2023
2023-12-28	TRILLIUM THERAPEUTICS USA, LLC	$16,470	Research payment	Cash or cash equivalent		A PHASE 1A1B DOSEESCALATION AND EXPANSION TRIAL OF TTI622 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES INCLUDING L	2023
2023-12-27	Genentech, Inc.	$69,760	Research payment	Cash or cash equivalent			2023
2023-12-27	Blueprint Medicines Corporation	$23,732	Research payment	Cash or cash equivalent		A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU	2023
2023-12-27	United Therapeutics Corporation	$9,198	Research payment	Cash or cash equivalent	TYVASO Drug, PAH	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj	2023
2023-12-27	Galderma Research & Development, LLC	$975	Research payment	Cash or cash equivalent		A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24	2023
2023-12-27	Blueprint Medicines Corporation	$950	Research payment	Cash or cash equivalent		An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat	2023
2023-12-26	Edwards Lifesciences Corporation	$14,799	Research payment	Cash or cash equivalent		Multi-scale modeling of SVC occlusion	2023
2023-12-25	Janssen Research & Development, LLC	$17,557	Research payment	Cash or cash equivalent		A Multi Center study of Androgen Suppression with abiraterone acetate Leuprolide PARP Inhibition and Stereotactic body r	2023
2023-12-22	Janssen Research & Development, LLC	$25,891	Research payment	Cash or cash equivalent		A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co	2023
2023-12-22	Janssen Research & Development, LLC	$17,082	Research payment	Cash or cash equivalent		A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Co	2023
2023-12-22	Merck Sharp & Dohme LLC	$5,689	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba	2023
2023-12-22	Aimmune Therapeutics, Inc.	$2,250	Research payment	Cash or cash equivalent		ARC008	2023
2023-12-22	Genentech, Inc.	$1,300	Research payment	Cash or cash equivalent	Venclexta Biological, BioOncology	Obinutuzumab Gazyva Polatuzumab Vedotin Venetoclax GDC 0199 in RR FL DLBCL	2023
2023-12-22	W. L. Gore & Associates, Inc.	$903	Research payment	Cash or cash equivalent	EXCLUDER Conformable AAA Endoprosthesis with Active Control Device, Devices	GORE EXCLUDER Conformable Endoprosthesis	2023
2023-12-22	Travere Therapeutics, Inc.	$552	Research payment	Cash or cash equivalent		021FSGS16010	2023
2023-12-22	Takeda Pharmaceuticals U.S.A., Inc.	$428	Research payment	Cash or cash equivalent	EXKIVITY Drug	A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$174	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$50	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$45	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$37	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$37	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$37	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$37	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023
2023-12-22	Regeneron Pharmaceuticals, Inc.	$37	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)	2023

The latest 200 records of 3,781.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Ann Arbor, MI, county Washtenaw County, MI, state Michigan; placed by its city name.

Measure	Place (city or town) Ann Arbor, MI	County Washtenaw County, MI	State Michigan
Population B01003	122,036	369,822	10,077,761
Population, 2020 census P1	123,851	372,258	10,077,331
Median age B01002	27.7	35.0	40.2
Under 18 B01001	12.4%	18.2%	21.2%
65 and over B01001	12.9%	15.7%	18.6%
Households B11001	50,499	150,550	4,076,369
Foreign born B05002	18.6%	13.1%	7.2%
Median household income B19013	$82,212	$89,180	$72,875
Median family income B19113	$146,116	$126,625	$93,357
Per capita income B19301	$55,459	$52,714	$40,735
Poverty rate B17001	23.8%	14.2%	13.2%
Unemployment rate B23025	3.9%	4.6%	5.7%
Civilian labor force B23025	65,177	195,907	5,018,449
Mean commute (minutes) B08013	20.0	23.5	24.2
Bachelor's degree or higher B15003	77.9%	58.7%	32.4%
Housing units B25001	54,399	159,782	4,622,236
Owner-occupied B25003	45.5%	61.6%	73.2%
Renters B25003	54.5%	38.4%	26.8%
Median home value B25077	$453,400	$374,100	$231,600
Median gross rent B25064	$1,649	$1,463	$1,129
White, not Hispanic B03002	66.5%	67.2%	72.4%
Black B03002	6.4%	11.3%	13.1%
Hispanic or Latino B03002	5.5%	5.8%	5.9%
Asian B03002	15.6%	9.2%	3.4%
American Indian and Alaska Native B03002	0.2%	0.2%	0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ann Arbor, MI.